Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Kroon HG, van Gils L, Ziviello F, van Wiechen M, Ooms J, Rahhab Z, El Faquir N, Maugenest AM, Kardys I, Daemen J, de Jaegere PP, Van Mieghem NM. Impact of baseline and newly acquired conduction disorders on need for permanent pacemakers with 3 consecutive generations of self-expanding transcatheter aortic heart valves. Cardiovasc Revasc Med 2021;34:40-45. [PMID: 33547024 DOI: 10.1016/j.carrev.2021.01.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/11/2020] [Accepted: 01/22/2021] [Indexed: 11/03/2022]

For:	Kroon HG, van Gils L, Ziviello F, van Wiechen M, Ooms J, Rahhab Z, El Faquir N, Maugenest AM, Kardys I, Daemen J, de Jaegere PP, Van Mieghem NM. Impact of baseline and newly acquired conduction disorders on need for permanent pacemakers with 3 consecutive generations of self-expanding transcatheter aortic heart valves. Cardiovasc Revasc Med 2021;34:40-45. [PMID: 33547024 DOI: 10.1016/j.carrev.2021.01.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/11/2020] [Accepted: 01/22/2021] [Indexed: 11/03/2022]

Number

Cited by Other Article(s)

Harvey JE, Puri R, Grubb KJ, Yakubov SJ, Mahoney PD, Gada H, Coylewright M, Poulin MF, Chetcuti SJ, Sorajja P, Rovin JD, Eisenberg R, Reardon MJ. Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves in a large real-world registry. CARDIOVASCULAR REVASCULARIZATION MEDICINE 2024:S1553-8389(24)00493-7. [PMID: 38871537 DOI: 10.1016/j.carrev.2024.05.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 04/29/2024] [Accepted: 05/17/2024] [Indexed: 06/15/2024]

Zheng HJ, Yan CJ, Lin DQ, Cheng YB, Yu SJ, Li J, Zhang XP, Cheng W. Prognostic impact of new permanent pacemaker implantation following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2023;102:743-750. [PMID: 37493466 DOI: 10.1002/ccd.30788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 06/26/2023] [Accepted: 07/19/2023] [Indexed: 07/27/2023]

Abstract

BACKGROUND

Conduction disturbances requiring permanent pacemaker implantation (PPI) are common following transcatheter aortic valve replacement (TAVR). There were conflicting data regarding the impact of new PPI on clinical outcomes after TAVR.

OBJECTIVES

The study sought to evaluate the impact of new PPI on clinical outcomes in patients undergoing TAVR.

METHODS

This study was a retrospective analysis of prospectively collected data. Data were from 210 consecutive patients without prior PPI who underwent TAVR due to severe symptomatic aortic stenosis at our center between June 2018 and July 2020. Clinical, echocardiographic, and pacing data were assessed at 30-day, 1- and 2-year follow-up.

RESULTS

New PPI was required in 35 (16.7%) patients within 30 days after TAVR. The median time from TAVR to PPI was 3 days. The most common indication for PPI was high-degree or complete atrioventricular block. The median follow-up was 798.0 (interquartile range, 669.0-1115.0) days. There were no differences in all-cause mortality (adjusted hazard ratio [HR]: 1.18; 95% confidence interval [CI]: 0.85-2.36; p = 0.415) and cardiovascular mortality (adjusted HR: 0.92; 95% CI: 0.57-1.89; p = 0.609) between groups. However, PPI group had a higher risk of heart failure (HF) rehospitalization (adjusted HR: 1.53; 95% CI: 1.26-2.28; p = 0.027). Echocardiography showed no significant improvement of LVEF over time in patients with PPI. At the latest follow-up, 31.3% of patients exhibited low (≤10%) pacing burdens, whereas 28.1% of patients had near constant (>90%) right ventricular pacing.

CONCLUSIONS

New PPI within 30 days following TAVR was not associated with an increased risk of all-cause or cardiovascular mortality. However, patients with PPI had a higher risk of HF rehospitalization and lack of LVEF improvement.

Collapse

Abdelshafy M, Elkoumy A, Elzomor H, Abdelghani M, Campbell R, Kennedy C, Kenny Gibson W, Fezzi S, Nolan P, Wagener M, Arsang-Jang S, Mohamed SK, Mostafa M, Shawky I, MacNeill B, McInerney A, Mylotte D, Soliman O. Predictors of Conduction Disturbances Requiring New Permanent Pacemaker Implantation following Transcatheter Aortic Valve Implantation Using the Evolut Series. J Clin Med 2023;12:4835. [PMID: 37510950 PMCID: PMC10381756 DOI: 10.3390/jcm12144835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Revised: 07/06/2023] [Accepted: 07/19/2023] [Indexed: 07/30/2023] Open

Abstract

(1) Background: Conduction disturbance requiring a new permanent pacemaker (PPM) after transcatheter aortic valve implantation (TAVI) has traditionally been a common complication. New implantation techniques with self-expanding platforms have reportedly reduced the incidence of PPM. We sought to investigate the predictors of PPM at 30 days after TAVI using Evolut R/PRO/PRO+; (2) Methods: Consecutive patients who underwent TAVI with the Evolut platform between October 2019 and August 2022 at University Hospital Galway, Ireland, were included. Patients who had a prior PPM (n = 10), valve-in-valve procedures (n = 8) or received >1 valve during the index procedure (n = 3) were excluded. Baseline clinical, electrocardiographic (ECG), echocardiographic and multislice computed tomography (MSCT) parameters were analyzed. Pre-TAVI MSCT analysis included membranous septum (MS) length, a semi-quantitative calcification analysis of the aortic valve leaflets, left ventricular outflow tract, and mitral annulus. Furthermore, the implantation depth (ID) was measured from the final aortography. Multivariate binary logistic analysis and receiver operating characteristic (ROC) curve analysis were used to identify independent predictors and the optimal MS and ID cutoff values to predict new PPM requirements, respectively; (3) Results: A total of 129 TAVI patients were included (age = 81.3 ± 5.3 years; 36% female; median EuroSCORE II 3.2 [2.0, 5.4]). Fifteen patients (11.6%) required PPM after 30 days. The patients requiring new PPM at 30 days were more likely to have a lower European System for Cardiac Operative Risk Evaluation II, increased prevalence of right bundle branch block (RBBB) at baseline ECG, have a higher mitral annular calcification severity and have a shorter MS on preprocedural MSCT analysis, and have a ID, as shown on the final aortogram. From the multivariate analysis, pre-TAVI RBBB, MS length, and ID were shown to be predictors of new PPM. An MS length of <2.85 mm (AUC = 0.85, 95%CI: (0.77, 0.93)) and ID of >3.99 mm (area under the curve (AUC) = 0.79, (95% confidence interval (CI): (0.68, 0.90)) were found to be the optimal cut-offs for predicting new PPM requirements; (4) Conclusions: Membranous septum length and implantation depth were found to be independent predictors of new PPM post-TAVI with the Evolut platform. Patient-specific implantation depth could be used to mitigate the requirement for new PPM.

Collapse

Affiliation(s)

Mahmoud Abdelshafy Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.) CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.) Department of Cardiology, Al-Azhar University, Cairo 11311, Egypt; (M.A.); (M.M.); (I.S.)
Ahmed Elkoumy Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.) CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.) Islamic Center of Cardiology and Cardiac Surgery, Al-Azhar University, Cairo 11651, Egypt
Hesham Elzomor Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.) CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.) Islamic Center of Cardiology and Cardiac Surgery, Al-Azhar University, Cairo 11651, Egypt
Mohammad Abdelghani Department of Cardiology, Al-Azhar University, Cairo 11311, Egypt; (M.A.); (M.M.); (I.S.) Department of Cardiology, Amsterdam UMC, Amsterdam Cardiovascular Sciences, University of Amsterdam, 1081 HV Amsterdam, The Netherlands
Ruth Campbell Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Ciara Kennedy Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
William Kenny Gibson Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Simone Fezzi Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Philip Nolan Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Max Wagener Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Shahram Arsang-Jang CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.) Discipline of Medicine, Clinical Science Institute, University of Galway, H91 YR71 Galway, Ireland
Sameh K. Mohamed CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.)
Mansour Mostafa Department of Cardiology, Al-Azhar University, Cairo 11311, Egypt; (M.A.); (M.M.); (I.S.)
Islam Shawky Department of Cardiology, Al-Azhar University, Cairo 11311, Egypt; (M.A.); (M.M.); (I.S.)
Briain MacNeill Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Angela McInerney Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.)
Darren Mylotte Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.) Discipline of Medicine, Clinical Science Institute, University of Galway, H91 YR71 Galway, Ireland
Osama Soliman Discipline of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, Health Service Executive, H91 YR71 Galway, Ireland; (M.A.); (A.E.); (H.E.); (R.C.); (C.K.); (W.K.G.); (S.F.); (P.N.); (M.W.); (B.M.); (A.M.) CORRIB Core Lab, University of Galway, H91 V4AY Galway, Ireland; (S.A.-J.); (S.K.M.) CÚRAM Centre for Medical Devices, H91 TK33 Galway, Ireland

Collapse

Elkoumy A, Mylotte D, Elzomor H, McInerney A, Soliman O. Emerging transcatheter heart valve technologies for severe aortic stenosis. Expert Rev Med Devices 2023;20:1065-1077. [PMID: 37933200 DOI: 10.1080/17434440.2023.2277229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 10/26/2023] [Indexed: 11/08/2023]

Nakashima M, Jilaihawi H. Conduction Disturbances and Pacing in Transcatheter Aortic Valve Replacement. Interv Cardiol Clin 2021;10:455-463. [PMID: 34593109 DOI: 10.1016/j.iccl.2021.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]